Cumberland Pharmaceuticals Inc. (CPIX) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

10/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 3

latest quarter score

Earnings Reports

10
Cumberland Pharmaceuticals (CPIX) Q2 2026: $100M Apotex Deal Reshapes Pipeline Funding and Strategic Focus
August 05, 2026
8
Cumberland Pharmaceuticals (CPIX) Q1 2026: $100M Apotex Deal Reshapes Business Model and Strategic Focus
May 06, 2026
19
Cumberland Pharmaceuticals (CPIX) Q4 2025: Vibative, Sancuso, and Talicia Drive 31% Revenue Surge, Global Expansion Accelerates
March 04, 2026
14
Cumberland Pharmaceuticals (CPIX) Q3 2025: Telicia Adds $8M Revenue Stream, Expands Infectious Disease Portfolio
November 05, 2025
23
Cumberland Pharmaceuticals (CPIX) Q2 2025: 23% Revenue Growth Accelerates Clinical and International Expansion
August 05, 2025
20
Cumberland Pharmaceuticals (CPIX) Q1 2025: 38% Revenue Growth Driven by FDA-Approved Brands and Strategic Expansion
May 06, 2025
Cumberland Pharmaceuticals (CPIX) Q4 2024: 11.6% Revenue Growth Highlights Pipeline and International Expansion
March 04, 2025

Browse all companies